|
Gene: TASP1 |
Gene summary for TASP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TASP1 | Gene ID | 55617 |
Gene name | taspase 1 | |
Gene Alias | C20orf13 | |
Cytomap | 20p12.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H6P5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55617 | TASP1 | CCI_2 | Human | Cervix | CC | 2.70e-12 | 1.05e+00 | 0.5249 |
55617 | TASP1 | CCI_3 | Human | Cervix | CC | 7.56e-14 | 8.79e-01 | 0.516 |
55617 | TASP1 | sample1 | Human | Cervix | CC | 1.53e-02 | 3.27e-01 | 0.0959 |
55617 | TASP1 | T1 | Human | Cervix | CC | 5.78e-09 | 3.66e-01 | 0.0918 |
55617 | TASP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.39e-22 | -6.90e-01 | 0.0155 |
55617 | TASP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.63e-03 | -5.14e-01 | -0.1808 |
55617 | TASP1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.49e-02 | -6.88e-01 | 0.0216 |
55617 | TASP1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.84e-05 | -4.98e-01 | -0.0811 |
55617 | TASP1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.62e-03 | -8.24e-01 | -0.2196 |
55617 | TASP1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.61e-07 | -6.59e-01 | -0.1207 |
55617 | TASP1 | HTA11_83_2000001011 | Human | Colorectum | SER | 8.70e-06 | -4.37e-01 | -0.1526 |
55617 | TASP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.47e-13 | -5.14e-01 | -0.1464 |
55617 | TASP1 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.62e-09 | -4.25e-01 | -0.1001 |
55617 | TASP1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 8.10e-03 | -7.05e-01 | -0.1706 |
55617 | TASP1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.69e-05 | -7.31e-01 | -0.2061 |
55617 | TASP1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 6.80e-04 | -7.17e-01 | -0.1462 |
55617 | TASP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.27e-03 | -4.23e-01 | 0.096 |
55617 | TASP1 | HTA11_4255_2000001011 | Human | Colorectum | SER | 4.38e-03 | -3.61e-01 | 0.0446 |
55617 | TASP1 | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.43e-02 | -8.08e-01 | 0.0451 |
55617 | TASP1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.71e-03 | -6.61e-01 | 0.0528 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00516048 | Cervix | CC | protein maturation | 56/2311 | 294/18723 | 5.90e-04 | 5.59e-03 | 56 |
GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
GO:00516042 | Colorectum | MSS | protein maturation | 75/3467 | 294/18723 | 1.70e-03 | 1.53e-02 | 75 |
GO:00516044 | Colorectum | CRC | protein maturation | 47/2078 | 294/18723 | 6.52e-03 | 4.70e-02 | 47 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
GO:005160416 | Oral cavity | LP | protein maturation | 122/4623 | 294/18723 | 1.37e-10 | 7.72e-09 | 122 |
GO:005160423 | Oral cavity | EOLP | protein maturation | 50/2218 | 294/18723 | 5.32e-03 | 2.77e-02 | 50 |
GO:005160432 | Oral cavity | NEOLP | protein maturation | 50/2005 | 294/18723 | 6.46e-04 | 5.47e-03 | 50 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TASP1 | SNV | Missense_Mutation | novel | c.603G>T | p.Arg201Ser | p.R201S | Q9H6P5 | protein_coding | tolerated(0.13) | benign(0.289) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
TASP1 | SNV | Missense_Mutation | novel | c.110A>G | p.Lys37Arg | p.K37R | Q9H6P5 | protein_coding | tolerated_low_confidence(0.66) | benign(0) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
TASP1 | insertion | Nonsense_Mutation | novel | c.1101_1102insCCAAAAGCAAAATAGATATGCTGGT | p.Phe368ProfsTer5 | p.F368Pfs*5 | Q9H6P5 | protein_coding | TCGA-D1-A102-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TASP1 | SNV | Missense_Mutation | c.551C>A | p.Pro184His | p.P184H | Q9H6P5 | protein_coding | deleterious(0.01) | possibly_damaging(0.879) | TCGA-ED-A7PZ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TASP1 | SNV | Missense_Mutation | novel | c.978G>T | p.Lys326Asn | p.K326N | Q9H6P5 | protein_coding | tolerated(0.16) | benign(0.376) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TASP1 | SNV | Missense_Mutation | novel | c.553N>G | p.Asn185Asp | p.N185D | Q9H6P5 | protein_coding | tolerated(0.52) | benign(0) | TCGA-91-8499-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TASP1 | SNV | Missense_Mutation | c.1013N>T | p.Gly338Val | p.G338V | Q9H6P5 | protein_coding | tolerated(0.23) | benign(0.124) | TCGA-21-1071-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TASP1 | SNV | Missense_Mutation | c.1045N>A | p.Cys349Ser | p.C349S | Q9H6P5 | protein_coding | tolerated(0.22) | benign(0.156) | TCGA-22-4599-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TASP1 | SNV | Missense_Mutation | novel | c.600N>C | p.Lys200Asn | p.K200N | Q9H6P5 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-60-2703-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TASP1 | SNV | Missense_Mutation | c.851N>G | p.Tyr284Cys | p.Y284C | Q9H6P5 | protein_coding | tolerated(0.1) | benign(0.198) | TCGA-60-2722-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | taxol | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
55617 | TASP1 | PROTEASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 252827510 |
Page: 1 |